NASDAQ$STTK
Shattuck Labs In · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Shattuck Labs reported its first quarter 2025 financial results, highlighting progress in its SL-325 program and maintaining a strong cash position.
Shattuck Labs reported a net loss of $13.7 million for Q1 2025, an improvement from the $18.5 million loss in Q1 2024. The company's cash and cash equivalents stood at $60.9 million, expected to fund operations into 2027. Key developments include the advancement of the SL-325 program with an IND filing expected in Q3 2025.
- Shattuck Labs reported a net loss of $13.7 million for the first quarter of 2025, compared to $18.5 million for the same period in 2024.
- Cash and cash equivalents were approximately $60.9 million as of March 31, 2025, with operations expected to be funded into 2027.
- The SL-325 program is on track for an IND filing in the third quarter of 2025, with the first patient in the Phase 1 clinical trial expected in the same quarter.
- Research and Development expenses decreased to $9.9 million in Q1 2025 from $16.3 million in Q1 2024, reflecting the completion of wind-down activities for discontinued oncology programs.
Headline financials
Revenue & EPS history
Shattuck Labs · Revenue · Quarterly
$0
Forward guidance
Shattuck Labs expects its current cash and cash equivalents to fund operations into 2027, beyond the results from its Phase 1 clinical trial for SL-325. The company anticipates an IND filing for SL-325 in Q3 2025 and expects to nominate a lead bispecific candidate from its preclinical pipeline in 2025.
Tailwinds
- IND filing for SL-325 expected in the third quarter of 2025.
- First patient in for the SAD portion of the Phase 1 clinical trial for SL-325 expected in the third quarter of 2025.
- Phase 1 enrollment completion for SL-325 expected in the second quarter of 2026.
- Company expects to nominate a lead bispecific candidate from its preclinical pipeline in 2025.
- Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027.
Headwinds
- Guidance excludes any additional capital that may be received.
- Guidance excludes proceeds from business development transactions.
- Guidance excludes additional costs associated with clinical development activities that may be undertaken.
- Actual results could be materially different from forward-looking statements due to various risks and uncertainties.
- The unpredictable relationship between preclinical study results and clinical study results could impact outcomes.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
-2.3%
Avg return
Earnings day
-3.1%
Avg return
5 days after
-1.1%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+10.7%
Q2 2020
Best reaction
-34.2%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.4% | -0.9% | -31.6% | |
| Q4 2025 | +7.8% | +26.0% | +35.7% | |
| Q3 2025 | -4.5% | -2.9% | +52.0% | |
| Q1 2025 | -0.1% | -3.7% | +21.3% | |
| Q4 2024 | -7.0% | -13.7% | -30.2% | |
| Q3 2024 | +1.6% | -6.6% | -6.6% | |
| Q2 2024 | -8.3% | -22.4% | -9.8% | |
| Q1 2024 | -0.7% | -1.0% | -32.0% | |
| Q4 2023 | +7.3% | +6.3% | -0.6% | |
| Q3 2023 | -22.4% | -12.2% | +0.0% | |
| Q2 2023 | -10.7% | -11.1% | -9.1% | |
| Q1 2023 | +3.3% | -3.7% | +8.6% | |
| Q4 2022 | +4.8% | +8.5% | -30.3% | |
| Q3 2022 | -12.2% | -6.8% | -0.4% | |
| Q2 2022 | -2.8% | +1.3% | -17.3% | |
| Q1 2022 | +4.9% | -0.9% | +27.3% | |
| Q4 2021 | +10.3% | +22.4% | -13.1% | |
| Q3 2021 | -34.2% | -34.5% | -51.8% | |
| Q2 2021 | +1.2% | -1.5% | -1.4% | |
| Q1 2021 | -3.5% | -9.2% | -2.7% | |
| Q4 2020 | -2.5% | -13.8% | -13.3% | |
| Q3 2020 | +10.7% | +4.9% | +40.2% | |
| Q2 2020 | +10.7% | +4.9% | +40.2% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro